Locoregional therapy for cholangiocarcinoma

@article{Kuhlmann2013LocoregionalTF,
  title={Locoregional therapy for cholangiocarcinoma},
  author={J. Kuhlmann and H. Blum},
  journal={Current Opinion in Gastroenterology},
  year={2013},
  volume={29},
  pages={324–328}
}
Purpose of review Cholangiocarcinoma has a poor prognosis. Surgical resection offers the only curative option and usually requires a major hepatic resection in addition to resection of the cholangiocarcinoma. Unfortunately, curative resection is possible in only about 30% of patients due to locally advanced disease, distant metastases or comorbidity in elderly patients. Even after resection, the recurrence rate is approximately 60%, resulting in a low 5-year overall survival (OS). In… Expand
Locoregional Therapy for Cholangiocarcinoma
TLDR
A review of emerging technologies and their potential role in treating cholangiocarcinoma explores locoregional therapies with thermal ablation and transarterial techniques. Expand
Hepatic intra-arterial and systemic chemotherapy followed by maintenance therapy for the treatment of cholangiocarcinoma.
TLDR
Cholangiocarcinoma patients may benefit from IAHCT-SCHT, and gemcitabine-based maintenance therapy (maintenance) may prolong clinical benefits. Expand
The role of interventional radiology in the treatment of intrahepatic cholangiocarcinoma
TLDR
The present review describes the current evidence of the interventional treatments in the management of the ICC and suggests interventional procedures available to increase the future liver reserve before surgery were analyzed. Expand
Liver transplantation in the management of perihilar cholangiocarcinoma.
TLDR
This review discusses the evolving role of liver transplantation in the management of patients with perihilar CCA (pCCA), and discusses the Mayo Clinic protocol of neoadjuvant chemoradiation followed by liver transplants in selected patients with pCCA. Expand
Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms: A review of the literature and a long-standing experience of a referral center.
TLDR
Patients should be promptly referred to a multidisciplinary team in a tertiary centre, familiar with this rare but lethal disease, based on the common guidelines and also on the clinical practice of multispecialist expert groups. Expand
Prognostic Impact of Tumor Growth Type on 7th AJCC Staging System for Intrahepatic Cholangiocarcinoma: a Single-Center Experience of 659 Cases
TLDR
Growth type of IHCC seems to be essential for determining tumor stage, and clear prognostic contrast was achieved among T1–3 stages with the redefined staging system with tumor growth types and risk factors. Expand
Diagnosis and systemic therapy for hepatobiliary cancer
TLDR
In HCC, therapy with the multikinase inhibitor sorafenib is established and new second-line therapies are expected, and gemcitabine and cisplatin is standard in first-line therapy. Expand
Effects of liver cirrhosis and patient condition on clinical outcomes in intrahepatic cholangiocarcinoma: a retrospective analysis of 156 cases in a single center
TLDR
The presence of liver cirrhosis A/B should not prevent patients with a good Eastern Cooperative Oncology Group Performance Status score from receiving tumor resection or chemotherapy from receiving chemotherapy, and patients’ general condition seems to be of more prognostic value in the treatment of iCCA than the presence of Cirrhosis. Expand
Palliation: treating patients with inoperable biliary tract and primary liver tumors.
TLDR
Palliative strategies including surgical, percutaneous, and endoscopic techniques to decompress the biliary system and improve symptoms are also summarized. Expand
Liver-Directed Therapy for Hepatic Malignancies
TLDR
This short review focuses on ablation and hepatic artery–directed therapies, and aims to provide a brief overview, indications for therapy, and outcomes from selected trials. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 20 REFERENCES
Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience.
TLDR
The chemoradiation given by SBRT plus gemcitabine is a promising treatment for non-metastatic unresectable KT and high local control rates, even compared to historical data from conventional radiotherapy, can be achieved with minimal toxicity. Expand
Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma.
TLDR
RFA may provide successful local tumor control in patients with primary intrahepatic cholangiocarcinomas of intermediate (3-5 cm) or small (< 3 cm) diameter, and percutaneous radiofrequency ablation was achieved for 15 of the 17 tumors, all smaller than 5 cm in diameter. Expand
Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success
TLDR
TACE is a palliative and safe treatment option for patients with unresectable CCC and prognostic factors governing treatment success, including initial tumor response, high tumor vascularity and Child‐Pugh class A were statistically significant factors for patient's survival. Expand
Transarterial Hepatic Yttrium-90 Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: Factors Associated with Prolonged Survival
TLDR
Radioembolization is an effective and safe option for patients with unresectable ICC and predictors for prolonged survival are performance status, tumor burden, and RECIST response. Expand
Adjuvant Transcatheter Arterial Chemoembolization for Intrahepatic Cholangiocarcinoma after Curative Surgery: Retrospective Control Study
TLDR
Adjuvant TACE after radical surgery was associated with better survival among the ICC patients with early recurrence, indicating that TACE could not delay recurrence but could prolong the OS of patients withEarly recurrence. Expand
Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma.
TLDR
TACE is safe and offers greater survival benefits than supportive treatment for the palliative treatment of unresectable ICC and the Kaplan-Meier survival analysis showed that the survival period was significantly longer in the TACE group than in the symptomatic treatment group. Expand
Stereotactic body radiotherapy for unresectable cholangiocarcinoma.
TLDR
The outcomes of SBRT for unresectable cholangiocarcinoma appear comparable to conventionally fractionated chemoradiotherapy with or without brachytherapy boost, and patient selection is key to avoid compromising such practical gains with excessive gastrointestinal toxicity. Expand
Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy
TLDR
This is the first study demonstrating that treatment of patients suffering from intrahepatic CCC with iDEB-TACE is safe in patients with normal liver function, and results in a prolongation of PFS and OS. Expand
Surgical Management of Intrahepatic Cholangiocarcinoma - A Population-Based Study
TLDR
Patients with localized CCA who are selected for CDS are strongly associated with improved survival, with rates approaching that found in single institution studies, however, many patients with localized tumors do not receive potentially curative cancer-directed surgery. Expand
Palliation of hepatic tumors.
TLDR
The therapeutic approaches to palliate hepatic tumors are reviewed, as well as how such therapies are designed to alleviate the symptoms of patients with end-stage liver tumors. Expand
...
1
2
...